Nevro HF10 therapy receives FDA approval for painful diabetic neuropathy — first SCS for this indication

Summary

Nevro received FDA approval for HF10 spinal cord stimulation for painful diabetic neuropathy, becoming the first SCS therapy approved for this indication. The SENZA-PDN pivotal trial demonstrated 76% of patients achieving 50% or greater pain relief at 3 months versus 6% for conventional medical management.